Pfizer Inc. (FRA:PFE)
20.21
+0.24 (1.21%)
Apr 25, 2025, 9:27 PM CET
Pfizer Revenue
In the year 2024, Pfizer had annual revenue of $63.63B USD with 6.84% growth. Pfizer had revenue of $17.76B in the quarter ending December 31, 2024, with 21.92% growth.
Revenue
$63.63B
Revenue Growth
+6.84%
P/S Ratio
1.86
Revenue / Employee
$785.52K
Employees
81,000
Market Cap
114.39B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 22.67B |
Bayer Aktiengesellschaft | 46.61B |
Fresenius SE & Co. KGaA | 21.83B |
Sartorius Aktiengesellschaft | 3.44B |
Fresenius Medical Care AG | 19.34B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
Pfizer News
- 12 hours ago - Earnings week ahead: MSFT, AAPL, META, AMZN, QCOM, PFE, MA, V, PYPL, ROKU, MCD, SBUX, KO, and more - Seeking Alpha
- 13 hours ago - Pfizer: I Am Locking In A 7.5% Dividend Yield Before Earnings - Seeking Alpha
- 17 hours ago - Pfizer (PFE) Reports Positive Phase 3 Results for Bladder Cancer Therapy - GuruFocus
- 1 day ago - Pfizer's Phase 3 CREST Trial Shows Promising Results for Sasanlimab in Bladder Cancer Treatment ... - GuruFocus
- 1 day ago - Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, ... - GuruFocus
- 1 day ago - Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer - Wallstreet:Online
- 1 day ago - Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer - Business Wire
- 2 days ago - US stocks end the week with a four day win streak - Forexlive